Search

everythinglearnresearchcommunity

for

Search:↓

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Bimekizumab effectively treated a man's chronic beard hair loss.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Ixekizumab has known and some unexpected side effects.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.

Anti-CD19 therapy may help treat SLE and NMOSD.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

The rash resolved after stopping ponatinib.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.

Biologics for severe asthma have known side effects, but some new risks need more study.

Tocilizumab might be an effective treatment for COVID-19.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Talquetamab may cause hair loss and skin issues.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.